Compare Quest Diagnostics Inc (DGX) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Centrus Energy Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Centrus Energy Corp trades at $142.44 (market cap $2.91B). The key difference: Quest Diagnostics Inc is far larger — about 8.8× Centrus Energy Corp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Centrus Energy Corp for 29 Days on average.
| DGX | LEU | |
|---|---|---|
Market Cap | $25.48B | $2.91B |
Volume | 941,866 | 903,777 |
Sector | Health | Energy |
52-Week High | $247.45 | $436.00 |
52-Week Low | $173.49 | $138.18 |
Typical Hold Time | 56 Days | 29 Days |
Enterprise Value | $31.23B | $2.22B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Centrus Energy (LEU) trades at $142.44, down 3.19% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) while profitability metrics remain solid (net margin 10.23%, ROE 8.05%). Recent news highlights the company's strategic position as a key HALEU supplier amid growing nuclear energy demand, with multiple new supply contracts announced in September 2026.
LEU presents a high-risk, high-reward opportunity with analyst consensus price target of $218.10 (53% upside) but significant execution risks. The company's growth depends on successful expansion of domestic uranium enrichment capacity and capitalizing on nuclear energy tailwinds, though recent profit margin compression and negative operating cash flow projections for 2026 warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
